With technology advancements dramatically improving the cost, accuracy, and time to map a person’s entire ... for people living with Duchenne muscular dystrophy amenable to exon 44 (DMD44).

CONNECT1 has enrolled two cohorts of boys and young men living with DMD amenable to exon 51 skipping and its endpoints include safety and tolerability, dystrophin production, exon skipping ...

a treatment for Duchenne muscular dystrophy or DMD in patients with exon 44 skipping amenable mutations. The company announced it has received authorization from the United Kingdom's Medicines and ...

Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...

Entrada Therapeutics plans to initiate ELEVATE-44-201 trial for ENTR-601-44 in Duchenne muscular dystrophy by Q2 2025. Entrada Therapeutics, Inc. announced that it has received regulatory ...

While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...

Entrada Therapeutics has secured authorisation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to ...

The authorization marks a significant step for Entrada, with CEO Dipal Doshi expressing the company's commitment to addressing the urgent needs of families affected by DMD. The upcoming trial will ...